20 May 2004
Coagulation inhibitors – antithrombin and protein C and periventricular leukomalacia in premature infants
Iwona Sadowska-Krawczenko, Małgorzata Ćwiklińska-Jurkowska, Piotr Korbal, Wiesław SzymańskiMed Sci Monit 2004; 10(2): 88-91 :: ID: 11852
Abstract
Background: Despite the great progress in neonatology since the 1990s, brain injury and neurodevelopmental impairment in the newborns remain common. Cranial imaging and neuropathology data indicate that periventricular leukomalacia can coexist with periventricular-intraventricular haemorrhage but they also may have separate pathogenic mechanisms. PVL refers to necrosis of the periventricular matter adjacent to the external angles of the lateral ventricles. The pathogenesis of this lesion relates to three major interacting factors: an incomplete state of development of the vascular supply to the cerebral white matter, a maturation-dependent impairment in regulation of cerebral blood flow and the maturation-dependent vulnerability of the oligodendroglial (OL) precursor cell that represents the major cellular target in PVL. The purpose of our study was to evaluate possible correlation between coagulation inhibitors and periventricular leukomalacia. Material/Methods: Serum samples were tested from 189 premature infants 20–30 minutes after delivery and on the 3rd day of life. Following laboratory tests were performed: C- reactive protein (12 hours after delivery), blood gases, blood cell count with smear, antithrombin activity, protein C activity, electrolytes. Arterial blood pressure was also measured.Results: 19 of 189 newborns were diagnosed with PVL according to cranial ultrasonography and neurological examination performed at the age of 2 months. In the group of children with PVL we have found lower activity of antithrombin and protein C in comparison to children without PVL.Conclusions: Etiology of periventricular leukomalacia is multifactorial and we conclude that activation of coagulation may have a significant effect on the patophysiology of this complication.
Keywords: antithrombin, periventricular leukomalacia, Protein C
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
15 Mar 2024 : Clinical Research
Impact of One-Lung Ventilation on Oxygenation and Ventilation Time in Thoracoscopic Heart Surgery: A Compar...Med Sci Monit In Press; DOI: 10.12659/MSM.943089
14 Mar 2024 : Clinical Research
Differential DHA and EPA Levels in Women with Preterm and Term Births: A Tertiary Hospital Study in IndonesiaMed Sci Monit In Press; DOI: 10.12659/MSM.943895
15 Mar 2024 : Clinical Research
Evaluation of an Optimized Workflow for the Radiofrequency Catheter Ablation of Paroxysmal Atrial FibrillationMed Sci Monit In Press; DOI: 10.12659/MSM.943526
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952